Evidence map›Paper›PMID 39432228›Full record

ArticleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2025

Levosimendan in Patients with Cardiogenic Shock Refractory to Dobutamine Weaning.

Michel Zeitouni, Elodie Dorvillius, David Sulman, Niki Procopi, Frederic Beaupré, Perrine Devos, Olivier Barthélémy, Stéphanie Rouanet, Arnaud Ferrante, Juliette Chommeloux and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michel Zeitouni *ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Elodie Dorvillius *ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
David SulmanACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Niki ProcopiACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Frederic BeaupréACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Perrine DevosACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Olivier BarthélémyACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Stéphanie RouanetStatistician Unit, StatEthic, ACTION Study group, Levallois-Perret, France.
Arnaud FerranteACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Juliette ChommelouxService de Médecine Intensive-Réanimation, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié-Salpêtrière, 47-83, Boulevard de l'Hôpital, 75651, CEDEX, Paris, France.
Guillaume HekimianService de Médecine Intensive-Réanimation, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié-Salpêtrière, 47-83, Boulevard de l'Hôpital, 75651, CEDEX, Paris, France.
Mathieu KerneisACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Johanne SilvainACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Gilles MontalescotACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France. gmontalescot@gmail.com.ORCID http://orcid.org/0000-0003-0824-6809
ACTION Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study examines the effects of levosimendan in patients refractory to dobutamine weaning.

methodsThis retrospective study included patients with cardiogenic shock refractory to dobutamine weaning failure admitted between 2010 and 2022. Patients treated with another type of dobutamine alone were compared with those treated with levosimendan in combination with dobutamine. Successful inotrope withdrawal was defined as survival without catecholamine support, transplant, or definitive ventricular assist device at 30 days. Secondary outcomes included all-cause mortality at 30 and 90 days.

resultsAmong 349 patients with cardiogenic shock and failure to withdraw from dobutamine, levosimendan was administered in combination with dobutamine in 114 patients, and another type of dobutamine alone was administered in 235 patients. At 30 days, successful inotrope withdrawal occurred in 46 (43.4%) patients taking levosimendan plus dobutamine versus 24 (10.5%) patients in the dobutamine-only group (weighted odds ratio [OR] 4.99, 95% confidence interval [CI] 2.65-9.38; p < 0.001), with similar results at 90 days (weighted OR 6.16, 95% CI 3.22-11.78; p < 0.001). Levosimendan + dobutamine was associated with lower 30-day mortality (weighted OR 0.47, 95% CI 0.26-0.84; p = 0.01), with no difference at 90 days (weighted OR 0.67, 95% CI 0.39-1.14; p = 0.14).

conclusionAdding levosimendan to dobutamine may improve inotrope withdrawal success and reduce 30-day mortality in patients with initial weaning failure.

Indexed as

Cardiotonic AgentsDobutamineShock, CardiogenicSimendanAgedDrug Therapy, CombinationFemaleHumansMaleMiddle AgedRetrospective StudiesCardiotonic AgentsDobutamineSimendan

Identifiers

PMID39432228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.